Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets

[1]  Tero Aittokallio,et al.  ePCR: an R-package for survival and time-to-event prediction in advanced prostate cancer, applied to real-world patient cohorts , 2018, Bioinform..

[2]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[3]  Jack Cuzick,et al.  Use of the concordance index for predictors of censored survival data , 2016, Statistical methods in medical research.

[4]  B. Fridley,et al.  An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients , 2016, F1000Research.

[5]  Søren Wengel Mogensen,et al.  Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients , 2016, F1000Research.

[6]  M. Gonen,et al.  UvA-DARE ( Digital Academic Repository ) Tailored care in resectable perihilar cholangiocarcinoma , 2015 .

[7]  R. Laing,et al.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.

[8]  J. Burke,et al.  Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. , 2015, The Lancet. Oncology.

[9]  Tapio Salakoski,et al.  Multi-label learning under feature extraction budgets , 2014, Pattern Recognit. Lett..

[10]  Ljubomir J. Buturovic,et al.  Cross-validation pitfalls when selecting and assessing regression and classification models , 2014, Journal of Cheminformatics.

[11]  M. Morris,et al.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[13]  C. Roehrborn,et al.  The economic burden of prostate cancer , 2011, BJU international.

[14]  P. Albers,et al.  Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Trevor Hastie,et al.  Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.

[16]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[17]  Tong Zhang,et al.  Trading Accuracy for Sparsity in Optimization Problems with Sparsity Constraints , 2010, SIAM J. Optim..

[18]  J. Goeman.  L1 Penalized Estimation in the Cox Proportional Hazards Model , 2009, Biometrical journal. Biometrische Zeitschrift.

[19]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Tong Zhang,et al.  Adaptive Forward-Backward Greedy Algorithm for Sparse Learning with Linear Models , 2008, NIPS.

[21]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[22]  Mee Young Park,et al.  L1‐regularization path algorithm for generalized linear models , 2007 .

[23]  Kim-Anh Do,et al.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. , 2007, Blood.

[24]  M. Kattan,et al.  Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Isabelle Guyon,et al.  An Introduction to Variable and Feature Selection , 2003, J. Mach. Learn. Res..

[27]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Geert M. P. van Kempen,et al.  On Feature Selection with Measurement Cost and Grouped Features , 2002, SSPR/SPR.

[29]  R. Tibshirani.  The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[30]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[31]  Thomas Yu,et al.  Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. , 2017, The Lancet. Oncology.

[32]  M. Moyad.  Docetaxel and Prednisone with or without Lenalidomide in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer ( MAINSAIL ) : A Randomised , Double-Blind , Placebo-Controlled Phase 3 Trial , 2015 .

[33]  Yichao Wu.  ELASTIC NET FOR COX'S PROPORTIONAL HAZARDS MODEL WITH A SOLUTION PATH ALGORITHM. , 2012, Statistica Sinica.